HOME >> MEDICINE >> NEWS
Predicting serious cardiac outcomes

Ischemia-modified albumin appears in the serum within minutes of ischemia, before myocete necrosis, and can be detected 6 hours or more after the onset of symptoms.

In this issue of CMAJ, Worster and colleagues describe how they evaluated the prognostic capabilities of high or low levels of ischemia-modified albumin in patients with potential cardiac-ischemia symptoms (within the preceding 6 hours) by recording outcomes such as death, myocardial infarction, heart failure, arrhythmia and refractory pain within 3 days of presentation. Their analysis, as underlined by Sabatine in a related commentary, showed that levels of ischemia-modified albumin provided no useful information in predicting which patients would have a serious cardiac outcome in the short term.


'"/>

Contact: Dr. Stephen Hill
hillstev@hhsc.ca
Canadian Medical Association Journal
20-Jun-2005


Page: 1

Related medicine news :

1. Predicting danger of flu pandemic rests on differences in affected population, says O.R. Forum
2. Predicting the quality of life for older adults
3. Predicting the risk of rheumatoid arthritis for early arthritis patients
4. Predicting an answer to the threat of flooding
5. Predicting outcomes for kidney transplant patients
6. Predicting successful outcomes in living-donor liver transplants
7. Predicting cardiovascular problems in liver transplant patients
8. Predicting the risk of death in patients with known coronary artery disease
9. Predicting the future of primary care in England
10. Predicting the outcome of drug-induced liver disease
11. Seat belt injuries could signal more serious trauma in children

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Predicting serious cardiac outcomes

(Date:4/17/2014)... LSTM have called for more research to be ... children in sub-Saharan Africa. In a paper in ... Russell Stothard, working with colleagues in the department ... University, in Cleveland Ohio, University of Cambridge and ... into the joint burden of HIV/AIDS and schistosomiasis ...
(Date:4/16/2014)... NJ (April 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: ... 1 study of CDX-1401 in solid tumors, including long-term ... Medicine (Vol 6 Issue 232). The data demonstrate ... clinical benefit in patients with very advanced cancers and ...
(Date:4/16/2014)... While it is well known that fertility treatments are ... that multiples are at elevated risk of premature birth, ... Fertility and Sterility . The article ... reduce the odds of multiple births and prematurity, including ...
(Date:4/15/2014)... medical mystery and in the process have found a potentially ... 1.5 million people a year. The researchers say they now understand ... been in use for more than 50 years even though ... to the microbes it attacks. , A report of ...
(Date:4/14/2014)... been made in chemotherapy over the past decade, but ... continues to be a major challenge. , Nanotechnology ... the use of nanocarriers, or capsules, that can transport ... body. , The catch? These carriers are tiny, and ...
Breaking Medicine News(10 mins):Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Nano shake-up 2
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
Cached News: